Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Autologous CD4+ and CD8+ T-cells transduced with lentiviral vector containing an affinity-enhanced T-cell receptor targeting the New York esophageal antigen-1

EU orphan designation number: EU/3/16/1694   
Active ingredient: Autologous CD4+ and CD8+ T-cells transduced with lentiviral vector containing an affinity-enhanced T-cell receptor targeting the New York esophageal antigen-1
Indication: Treatment of soft tissue sarcoma
Sponsor: GlaxoSmithKline Trading Services Limited
Currabinny, Carrigaline, County Cork, Ireland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
18/07/2016 Orphan designation EMA/OD/064/16 (2016)4679 of 14/07/2016
7/08/2018 Transfer of orphan designation EMA/OD/064/16/T/01 (2018)5405 of 3/08/2018